RobertLawrenceMartuzaMD

Brain & Spinal Tumor, Skull Base

William and Elizabeth Sweet Professor of Neuroscience in the Department of Surgery, Mass Gen Hosp

Dr. Martuza is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
55 Fruit St
Wht 502 Neurosurgery Mgh
Boston, MA 02114
Phone+1 617-726-8581

Fax+1 617-726-4814

PubMed

249 citations
Molecular genetic approach to human meningioma: loss of genes on chromosome 22
Bernd R. Seizinger, S de la Monte, Leonard Atkins, James F. Gusella, Robert L. Martuza
Proceedings of the National Academy of Sciences of the United States of America. 1987-08-01
3031 citations
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Anoop P. Patel, Itay Tirosh, John J. Trombetta, Alex K. Shalek, Shawn M. Gillespie
Science. 2014-06-20
49 citations
Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma
Juri Kiyokawa, Yoichiro Kawamura, Shanawaz M. Ghouse, Simge Acar, Erinç Barçın
Clinical Cancer Research. 2021-02-01

Journal Articles

Sequestration of T Cells in Bone Marrow in the Setting of Glioblastoma and Other Intracranial Tumors
Peter E Fecci, Cosette A Dechant, Robert L Martuza, Karolina Woroniecka, Brian V Nahed, James E Herndon, William T Curry, Aladine A Elsamadicy, John H Sampson, Michael..., Nature

Histopathological Prognostic Factors of Recurrence Following Definitive Therapy for Atypical and Malignant Meningiomas RelatedApril 2018
Histopathological Prognostic Factors of Recurrence Following Definitive Therapy for Atypical and Malignant Meningiomas RelatedApril 2018
Histopathological Prognostic Factors of Recurrence Following Definitive Therapy for Atypical and Malignant Meningiomas RelatedApril 2018
Histopathological Prognostic Factors of Recurrence Following Definitive Therapy for Atypical and Malignant Meningiomas RelatedApril 2018
Join now to see all

Brain Infusion of Genetically Modified Poliovirus Is Used to Treat GlioblastomaAugust 19th, 2019
'Passion of a Surgeon'September 1st, 2017
The One Symptom of a Brain Tumor You Should Never Ignore Is Actually Really CommonSeptember 27th, 2016
Join now to see all

Neuroscience Resident Research ProgramNational Institute Of Neurological Disorders And Stroke2009–2012
Genetically Engineered Viruses For Prostate Cancer TherapyNational Cancer Institute2007–2012
Genetically Engineered Viruses For Brain Tumor TherapyNational Institute Of Neurological Disorders And Stroke2000–2012
Training Program In Nervous System TumorsNational Cancer Institute2006–2007
Genetically Engineered Viruses For Prostate Cancer TherNational Cancer Institute2004–2006
Clinical Research Training Program In NeurooncologyNational Cancer Institute2001–2005
Genetically Engineered Viruses For Brain Tumor TherapyNational Institute Of Neurological Disorders And Stroke1994–1999
National CNS Tumor ConsortiumNational Cancer Institute1994–1997
Molecular Targeting Of Therapy For Nervous System TumorsNational Cancer Institute1993–1995
Hormonal Modulation Of NeurofibromatosisNational Institute Of Neurological Disorders And Stroke1985–1988
Neurofibromatosis: Cellular Features, Hormonal ControlsNational Institute Of Neurological Disorders And Stroke1985–1986